Guidelines on “Similar Biologics: Regulatory requirements for Market Authorization in India” will be implemented from 15th September 2012.
The “Guidelines on Similar Biologics” prepared by Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) lay down the regulatory pathway for a similar biologic claiming to be similar to an already authorized reference biologic.
The guidelines address the regulatory pathway regarding manufacturing process and quality aspects for similar biologics.
These guidelines also address the pre-market regulatory requirements including comparability exercise for quality, preclinical and clinical studies and post market regulatory requirements for similar biologics.
For further details visit
https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NTU0NA==
Recent Posts
India as a Cosmetic Manufacturing Hub: CDSCO, BIS, and the Regulatory Enablers for Global Manufacturers
The Strategic Shift For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing ..
Post-Market Surveillance Under Medical Device Rules, 2017
Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance ..
How to Sequence Global and India Market Entry for Medical Devices Without Creating Regulatory Rework
One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions because the..
Need Help?
Submit your EnquiryOffice Locations
- Delhi
- Bangalore
- USA
- Singapore